Filtered By:
Drug: Rituxan
This page shows you your search results in order of date. This is page number 20.
Order by Relevance | Date
Total 5036 results found since Jan 2013.
Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study
CONCLUSIONS: The addition of rituximab to conventional chemotherapy for CD20-positive ALL is effective and tolerable (Clinicaltrials. gov NCT01429610).PMID:37334511 | DOI:10.3904/kjim.2022.401
Source: The Korean Journal of Internal Medicine - June 19, 2023 Category: Internal Medicine Authors: Dong Won Baek Han-Seung Park Sang Kyun Sohn Dae Young Kim Inho Kim Jae-Sook Ahn Young Rok Do Se Ryeon Lee Hyeon-Seok Eom Won-Sik Lee Sung-Hyun Kim Ho Sup Lee Yoo Jin Lee Joon Ho Moon Je-Hwan Lee Adult Acute Lymphoblastic Leukemia Working Party, the Korean Source Type: research
Delayed spontaneous remission of acquired factor V inhibitor refractory to immunosuppressive therapy with pregnancy-associated improvement
Discussion: The use of an activated bypassing agent for bleeding control is effective in patients with severe AFVI. The presented case is unique because the treatment regimens included multiple combinations of immunosuppressive agents. This demonstrates that AFVI patients may undergo spontaneous remission even after multiple courses of ineffective immunosuppressive protocols. Additionally, pregnancy-associated improvement of AFVI is an important finding that warrants further investigation.PMID:37334173 | PMC:PMC10272408 | DOI:10.3389/pore.2023.1611250
Source: Pathology Oncology Research - June 19, 2023 Category: Pathology Authors: Andrea Cegl édi J ános Dolgos M ónika Fekete L ászló Gopcsa Andrea V árkonyi Be áta Vilimi G ábor Mikala Imre Bod ó Source Type: research
Rituximab plus multiagent chemotherapy for newly diagnosed CD20-positive acute lymphoblastic leukemia: a prospective phase II study
CONCLUSIONS: The addition of rituximab to conventional chemotherapy for CD20-positive ALL is effective and tolerable (Clinicaltrials. gov NCT01429610).PMID:37334511 | DOI:10.3904/kjim.2022.401
Source: The Korean Journal of Internal Medicine - June 19, 2023 Category: Internal Medicine Authors: Dong Won Baek Han-Seung Park Sang Kyun Sohn Dae Young Kim Inho Kim Jae-Sook Ahn Young Rok Do Se Ryeon Lee Hyeon-Seok Eom Won-Sik Lee Sung-Hyun Kim Ho Sup Lee Yoo Jin Lee Joon Ho Moon Je-Hwan Lee Adult Acute Lymphoblastic Leukemia Working Party, the Korean Source Type: research
Dysthyroid optic neuropathy: emerging treatment strategies
ConclusionOnly a limited number of studies have been dedicated to the therapy of DON, mostly retrospective with a small sample size. Clear criteria regarding diagnosis and resolution of DON do not exist, which restricts comparison of therapeutic outcomes. Randomized clinical trials and comparison studies with long-term follow-ups are necessary to verify the safety and efficacy of each therapeutic option for DON.
Source: Journal of Endocrinological Investigation - June 15, 2023 Category: Endocrinology Source Type: research
Impact of monoclonal protein at diagnosis on outcomes in marginal zone lymphoma: A multicenter cohort study
Blood Adv. 2023 Jun 14:bloodadvances.2023010133. doi: 10.1182/bloodadvances.2023010133. Online ahead of print.ABSTRACTGiven the paucity of data surrounding the prognostic relevance of monoclonal paraprotein (M-protein) in marginal zone lymphoma (MZL), we sought to evaluate the impact of M-protein at diagnosis on outcomes in MZL patients in a large retrospective cohort. The study included 547 patients receiving first-line therapy for MZL. M-protein was detectable at diagnosis in 173 (32%) patients. There was no significant difference in the time from diagnosis to initiation of any therapy (systemic and local) between the M-...
Source: Adv Data - June 14, 2023 Category: Epidemiology Authors: Narendranath Epperla Qiuhong Zhao Reem Karmali Pallawi Torka Lauren Shea Timothy S Oh Andrea Anampa-Guzm án Heather Reves Montreh Tavakkoli Irl Brian Greenwell Emily Hansinger Elvira Umyarova Kaitlin Annunzio Yazeed Sawalha Beth Christian Colin Thomas St Source Type: research
Dysthyroid optic neuropathy: emerging treatment strategies
ConclusionOnly a limited number of studies have been dedicated to the therapy of DON, mostly retrospective with a small sample size. Clear criteria regarding diagnosis and resolution of DON do not exist, which restricts comparison of therapeutic outcomes. Randomized clinical trials and comparison studies with long-term follow-ups are necessary to verify the safety and efficacy of each therapeutic option for DON.
Source: Journal of Endocrinological Investigation - June 12, 2023 Category: Endocrinology Source Type: research
Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using < sup > 90 < /sup > Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma
CONCLUSION: Addition of Zevalin to Flu/Mel is safe and effective in high-risk NHL and met the prespecific endpoint. Results were suboptimal in patients with DLBCL.PMID:37301631 | DOI:10.1016/j.clml.2023.05.011
Source: Clinical Lymphoma and Myeloma - June 10, 2023 Category: Cancer & Oncology Authors: Matthew Mei Joycelynne Palmer Nicole Ni-Chun Tsai Jennifer Simpson James O'Hearn Anthony Stein Stephen Forman Ricardo Spielberger Ji-Lian Cai Myo Htut Ryotaro Nakamura Monzr M Al Malki Alex Herrera Jeffrey Wong Auayporn Nademanee Source Type: research
Clinical and Prognostic Factors in Patients with IgG4-Related Kidney Disease
CONCLUSIONS: IgG4-related kidney disease predominantly affected middle-aged males and manifested as tubulointerstitial nephritis with potential glomerular involvement. Complement consumption and the number of organs involved were associated with a higher relapse rate, whereas first-line therapy with Rituximab was associated with lower. Patients with high serum IgG4 concentrations (≥5g/L) had more severe kidney disease.PMID:37283461 | DOI:10.2215/CJN.0000000000000193
Source: Clinical Journal of the American Society of Nephrology : CJASN - June 7, 2023 Category: Urology & Nephrology Authors: Anis Chaba Arnaud Devresse Vincent Audard Jean Jacques Boffa Alexandre Karras Claire Cartery Cl ément Deltombe Jonathan Chemouny Claudine Contamin Cecille Courivaud Simon Duquennoy Hugo Garcia Dominique Joly Nabila Goumri Guillaume Hanouna Jean Michel Ha Source Type: research
Within-Host Evolution of SARS-CoV-2 in a B-Cell Depleted Patient With Successful Treatment
J Korean Med Sci. 2023 Jun 5;38(22):e175. doi: 10.3346/jkms.2023.38.e175.ABSTRACTProlonged viral shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an immunocompromised host is a challenge as the treatment and infection control for chronic coronavirus disease 2019 infection is not well established and there is a potential risk of new variants emerging. A 48-year-old woman who underwent chemotherapy, including rituximab and steroid, had reactivation of SARS-CoV-2 68 days after the virus was first detected. She successfully recovered after receiving convalescent plasma and intravenous immunoglobulin....
Source: J Korean Med Sci - June 5, 2023 Category: General Medicine Authors: Yae Jee Baek Gemma Park Jun Yong Choi Eun Jin Kim Bryan Inho Kim Jin Gwack Ji Ye Jung Source Type: research
Infectious risk when prescribing rituximab in patients with hypogammaglobulinemia acquired in the setting of autoimmune diseases
Int Immunopharmacol. 2023 Jun 3;120:110342. doi: 10.1016/j.intimp.2023.110342. Online ahead of print.ABSTRACTWe conducted a single-centre retrospective cohort study in a French University Hospital between 2010 and 2018 to describe the risk of severe infectious event (SIE) within 2 years after the date of first rituximab infusion (T0) prescribed after the evidence of acquired hypogammaglobulinemia (gamma globulins [GG] ≤ 6 g/L) in the setting of autoimmune diseases (AID) other than rheumatoid arthritis. SIE occurred in 26 out of 121 included patients. Two years cumulative incidence rates were 12.7 % (95 % CI 5.1-23.9) in ...
Source: International Immunopharmacology - June 5, 2023 Category: Allergy & Immunology Authors: Xavier Boumaza Margaux Lafaurie Emmanuel Treiner Ondine Walter Gregory Pugnet Guillaume Martin-Blondel Damien Biotti Jonathan Ciron Arnaud Constantin Marie Tauber Florent Puisset Guillaume Moulis Laurent Alric Yves Renaudineau Dominique Chauveau Laurent S Source Type: research
Within-Host Evolution of SARS-CoV-2 in a B-Cell Depleted Patient With Successful Treatment
J Korean Med Sci. 2023 Jun 5;38(22):e175. doi: 10.3346/jkms.2023.38.e175.ABSTRACTProlonged viral shedding of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in an immunocompromised host is a challenge as the treatment and infection control for chronic coronavirus disease 2019 infection is not well established and there is a potential risk of new variants emerging. A 48-year-old woman who underwent chemotherapy, including rituximab and steroid, had reactivation of SARS-CoV-2 68 days after the virus was first detected. She successfully recovered after receiving convalescent plasma and intravenous immunoglobulin....
Source: J Korean Med Sci - June 5, 2023 Category: General Medicine Authors: Yae Jee Baek Gemma Park Jun Yong Choi Eun Jin Kim Bryan Inho Kim Jin Gwack Ji Ye Jung Source Type: research
